Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Impact of Tele-interventions During the COVID-19 Pandemic in Patients With Diabetes Mellitus

11 ottobre 2020 aggiornato da: Janine Alessi, Federal University of Rio Grande do Sul

Impact of Tele-Interventions During the COVID-19 Pandemic on Glycemic Control and Attitude Toward the Disease in Patients With Diabetes Mellitus - A Randomized Clinical Trial

INTRODUCTION In critical situations, such as the current COVID 19 pandemic, themes of fear, uncertainty and stigmatization are common and constitute barriers to appropriate medical and mental health interventions. These challenges, when faced by those who live with a chronic disease, such as diabetes mellitus (DM), can negatively influence quality of life and adherence to treatment, compromising the control of the disease.

OBJECTIVES The present study aims to investigate the effectiveness of a tele-intervention during the COVID-19 pandemic in improving glycemic control, lipid profile, blood pressure levels and parameters of medication adherence, mental well-being and sleep quality in patients with type 1 DM and type 2 DM.

METHODS A randomized clinical trial will be carried out with patients with a previous diagnosis of type 1 DM and type 2 DM, who are registered at the Hospital de Clínicas de Porto Alegre (HCPA). Inclusion criteria will be age greater than or equal to 18 years, collection of HbA1c in the HCPA laboratory in January, February or March 2020 and availability to receive weekly phone calls. Patients will be randomized, stratified by type of diabetes, in two groups: G1: participants will receive a tele-intervention by a case manager weekly to discuss topics related to diabetes management and mental well-being during the social distancing period ; G2: participants will receive the usual care. The primary outcome assessed will be the variation in HbA1c levels comparatively between groups, with or without a tele-guided strategy, after four months of social distancing (or as long as the recommendation of social distancing measures remains). Secondary outcomes will include experiencing confirmation of COVID-19 infection, variation in lipid profile, blood pressure levels and variation in parameters of emotional distress related to diabetes, eating disorders, medication adherence, symptoms minor psychiatric disorders and altered sleep patterns, which will be evaluated with specific and validated scales. According to the sample calculation, 150 patients will be included in the study (92 with type 2 DM and 58 with type 1 DM). Analysis by intention to treat will be performed separately for patients with type 1 DM and with type 2 DM.

SCHEDULE The proposed experiment will start immediately after approval of this project by the research ethics committee. The duration of the proposed intervention is 4 months (or as long as the recommendation of social distancing measures remains. This means that the study may be completed before or after that period, based on national recommendations for social distancing in Brazil), with a data analysis plan and publication of the results until September 2020.

Panoramica dello studio

Tipo di studio

Interventistico

Iscrizione (Effettivo)

149

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

    • Rio Grande Do Sul
      • Porto Alegre, Rio Grande Do Sul, Brasile, 90620-170
        • Hospital de Clínicas de Porto Alegre

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • Type 1 diabetes mellitus or type 2 diabetes mellitus;
  • Age greater than or equal to 18 years;
  • HbA1c assessed in January, February or March 2020;
  • Availability to receive weekly phone calls

Exclusion Criteria:

  • Any severe cognitive limitation that prevents the necessary interaction to carry out this study (advanced dementia, deafness, dysarthria, aphasia);
  • Do not present a telephone record in an electronic medical record;

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Terapia di supporto
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Tele-Intervention
Participants will receive a tele-intervention by a case manager weekly to discuss topics related to diabetes management and mental well-being during the quarantine period
Participants will receive a tele-intervention by a case manager weekly to discuss topics related to diabetes management and mental well-being during the quarantine period
Nessun intervento: Usual Care
Participants will receive the usual care

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Variation in HbA1c levels
Lasso di tempo: 4 months (or as long as the recommendation of social distancing measures remains)
Variation in HbA1c levels comparatively between groups after the period of social distancing measures.
4 months (or as long as the recommendation of social distancing measures remains)

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
COVID-19 infection
Lasso di tempo: 4 months (or as long as the recommendation of social distancing measures remains)
Confirmation of coronavirus infection by rapid test
4 months (or as long as the recommendation of social distancing measures remains)
Variation in lipid profile
Lasso di tempo: 4 months (or as long as the recommendation of social distancing measures remains)
Comparison of the lipid profile of the last year with the lipid profile after the intervention between the groups.
4 months (or as long as the recommendation of social distancing measures remains)
Variation in blood pressure levels
Lasso di tempo: 4 months (or as long as the recommendation of social distancing measures remains)
Comparison of the blood pressure level of the last consultation with the pressure after the intervention between the groups.
4 months (or as long as the recommendation of social distancing measures remains)
Comparison of emotional distress associated with the routine of living with diabetes after intervention between groups
Lasso di tempo: 4 months (or as long as the recommendation of social distancing measures remains)
Evaluation of emotional distress associated with the routine of living with diabetes - B-PAID (Brazilian Problem Areas In Diabetes Scale)
4 months (or as long as the recommendation of social distancing measures remains)
Comparison of eating disorders between groups
Lasso di tempo: 4 months (or as long as the recommendation of social distancing measures remains)
Evaluation of eating disorders - EAT - 26 SCALE (Teste de Atitudes Alimentares)
4 months (or as long as the recommendation of social distancing measures remains)
Comparison of adherence to the proposed clinical treatment between groups
Lasso di tempo: 4 months (or as long as the recommendation of social distancing measures remains)
Evaluation of adherence to the proposed clinical treatment - SCI R (Self-Care Inventory - revised)
4 months (or as long as the recommendation of social distancing measures remains)
Comparison of minor psychiatric disorders between groups
Lasso di tempo: 4 months (or as long as the recommendation of social distancing measures remains)
Evaluation of minor psychiatric disorders - SRQ 20 (Self Report Questionnaire)
4 months (or as long as the recommendation of social distancing measures remains)
Comparison of sleep pattern changes between groups
Lasso di tempo: 4 months (or as long as the recommendation of social distancing measures remains)
Evaluation of sleep pattern changes - MSQ (Mini Sleep Questionnaire)
4 months (or as long as the recommendation of social distancing measures remains)

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

17 aprile 2020

Completamento primario (Effettivo)

20 settembre 2020

Completamento dello studio (Effettivo)

20 settembre 2020

Date di iscrizione allo studio

Primo inviato

7 aprile 2020

Primo inviato che soddisfa i criteri di controllo qualità

10 aprile 2020

Primo Inserito (Effettivo)

14 aprile 2020

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

14 ottobre 2020

Ultimo aggiornamento inviato che soddisfa i criteri QC

11 ottobre 2020

Ultimo verificato

1 ottobre 2020

Maggiori informazioni

Termini relativi a questo studio

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

Tipo di informazioni di supporto alla condivisione IPD

  • STUDIO_PROTOCOLLO
  • LINFA
  • ICF
  • CODICE_ANALITICO
  • RSI

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi